Development of a CD3 VHH Platform that Enables the Rapid Testing of Multiple T-Cell Engager Configurations for Optimal Use Cases
Time: 1:30 pm
day: Day Two
Details:
- Discussing the development of identifying and engineering a cyno-cross reactive CD3 VHH platform with properties suitable for either oncology or immunology
- Demonstrating the ease of evaluating multiple CD20 TCE configurations with the CD3 VHH binding arm to determine an optimal lead
- Brief overview on how a CD3 VHH simplifies the development of the next generation of T cell engagers
